[The impact of a new family among the therapeutic strategies: the immunologist's point of view].
Corbeau
P
P
Immunologie, Hôpital Carémeau, Place du Pr. Robert Debré - 30029 Nîmes cedex 9, France; Immunologie, Hôpital Saint-Eloi, 191, avenue du Doyen Gaston Giraud, 34295 Montpellier cedex 5, France.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D001424:Bacterial Infections / Q000276:immunology; D018988:Bacterial Translocation; D065100:CCR5 Receptor Antagonists; D018791:CD4 Lymphocyte Count; D016207:Cytokines / Q000502:physiology; D004359:Drug Therapy, Combination; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007107:Immune System / Q000187:drug effects; D016867:Immunocompromised Host; D008213:Lymphocyte Activation / Q000187:drug effects; D019713:Receptors, CCR5 / Q000235:genetics / Q000276:immunology / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000821:virology; D014777:Virus Diseases / Q000276:immunology
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; C584933:CCR5 protein, human; D016207:Cytokines; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5